Vertex Pharmaceuticals (VRTX -12.3%) slides on weaker-than-expected Q3 results and a downgrade to Neutral by Goldman. Citing the weak results and the recent NACFC conference, Goldman says it's formed a more cautious outlook on the company's key pipeline program, and sees a limited number of upside catalysts heading into 2013.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs